Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03511521 · ClinicalTrials.gov registry record · Phase 4
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
A Phase 4 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03511521 is a Phase 4 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 3 participants.
The verdict
NCT03511521, a Phase 4 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
Glucocorticoids are known to cause an increase in insulin resistance, leading to hyperglycemia, in both diabetic and non-diabetic patients. In both the inpatient and outpatient setting, steroids are used for their anti-inflammatory property to treat a variety of conditions. There is a paucity of information regarding the best way to treat steroid-induced hyperglycemia. In this study we will compare (1) the addition of NPH insulin, an intermediate-acting insulin, given at the time of steroid administration to the patient's standard basal/bolus insulin to (2) modification of the standard basal-bolus insulin regimen which will consist primarily increasing the prandial doses at lunch and supper in order to determine which regimen is superior for glycemic control.
Interventions
- DRUG NPH Insulin
- DRUG Insulin Aspart
- DRUG glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-03-27 |
| Est. Completion | 2019-08-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03511521
The ClinicalTrials.gov registry entry for NCT03511521 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which NPH Insulin is the first listed.
NCT03511521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03511521 about?
NCT03511521 is a clinical study titled "Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia". Glucocorticoids are known to cause an increase in insulin resistance, leading to hyperglycemia, in both diabetic and non-diabetic patients. In both the inpatient and outpatient setting, steroids are used for their anti-inflammatory property to treat a variety of conditions. There is a paucity of inf...
What is the current status of trial NCT03511521?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2018-03-27. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT03511521?
The interventions under investigation include: NPH Insulin (DRUG), Insulin Aspart (DRUG), glargine (DRUG).
Who is sponsoring clinical trial NCT03511521?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.